Nkarta (NKTX) News
NASDAQ: NKTXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
1.14+0.015 (+1.34%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
NKTX news summary
We found 6 recent headlines mentioning Nkarta (NKTX): 0 in the past week and 6 in the past 30 days, most often from GlobeNewswire, Nasdaq. For price context, NKTX is up 1.34% at $1.14. The most recent story, "Nkarta Presents Initial Safety Data for NKX019 in 40 Patients Across Five Autoimmune Diseases at ACR Convergence 2026", was published by GlobeNewswire on Nov 11, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Nkarta headlines
- Nkarta Presents Initial Safety Data for NKX019 in 40 Patients Across Five Autoimmune Diseases at ACR Convergence 2026SOUTH SAN FRANCISCO, Calif., Nov. 11, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biotechnology company developing engineered natural killer (NK) cell therapies to treat…GlobeNewswire
- Nkarta, Inc. Announces Initial Clinical Data for NKX019 in Myositis and Systemic SclerosisOn November 9, 2026, Nkarta, Inc. announced initial clinical data from its ongoing Phase 1/2 Ntrust-2 basket study evaluating NKX019, its allogeneic, off-the-shelf, CD19-directed chimeric antigen…NasdaqNKTX, ET
- Nkarta Announces Initial Clinical Data for NKX019 in Myositis and Systemic Sclerosis at ACR ConvergenceSOUTH SAN FRANCISCO, Calif., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Nkarta (Nasdaq: NKTX), a clinical-stage biotechnology company developing engineered natural killer (NK) cell therapies to treat…GlobeNewswire
- Nkarta, Inc. to Host Webcast to Discuss Initial Clinical Data for NKX019 at ACR Convergence 2026Nkarta, Inc. announced that it will host a webcast on Monday, November 9, 2026, at 8:00 a.m. Eastern Time to review initial clinical data from its Ntrust clinical program evaluating NKX019 in…Nasdaq
- Nkarta to Host Webcast to Discuss Initial Clinical Data for NKX019 in Autoimmune Diseases at ACR Convergence 2026SOUTH SAN FRANCISCO, Calif., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biotechnology company developing engineered natural killer (NK) cell therapies to treat…GlobeNewswire
- Nkarta Reports Third Quarter 2026 Financial Results and Provides Business UpdateSOUTH SAN FRANCISCO, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biotechnology company developing engineered natural killer (NK) cell therapies to treat…GlobeNewswire